摘要
目的:研究虎杖苷对肝纤维化的治疗作用。方法:使用腹腔注射CCl4构建C57小鼠的肝纤维化模型,同时采用虎杖苷腹腔注射进行治疗。检测血清ALT水平以判断肝脏损伤情况,运用组织病理观察和天狼猩红染色观察肝纤维化情况,使用人源肝星状细胞系LX-2细胞给药干预后采用Western blot检测TGF-β1和α-SMA蛋白的表达情况。结果:相较于CCl4组,虎杖苷治疗组小鼠血清ALT水平明显降低,差异具有统计学意义(P<0.05)。虎杖苷显著下调LX-2细胞系中TGF-β1和α-SMA的蛋白表达。结论:虎杖苷具有良好的抗肝纤维化作用,其作用可能与抑制TGF-β1有关。
Objective： To investigate the pharmacological effects of polydatin about the treatment of liver fibrosis. Methods： C57 mice were used to induce liver fibrosis model by injecting CC14 intraperitoneally. For the treatment group,mice were treated with in- traperitoneal injection of polydatin. Using serum ALT to determine liver injury, pathological staining and Sirius red staining were ap- plied to determine liver fibrosis. Using human hepatic stellate cells line LX-2 to administrate polydatin and using Western blot to de- tect the protein expression of TGF-131 and c^-SMA. Results ： Compared with CC14 group, ALT in polydatin group marked reduced. Polydatin significantly reduced the protein expression levels of TGF-t31 and a-SMA in the LX-2 cell line. Conclusion ： Polydatin can significantly ameliorate liver fibrosis and this effect may depend on the inhibition of TGF-β1.
出处
《亚太传统医药》
2017年第16期14-16,共3页
Asia-Pacific Traditional Medicine
基金
广东省自然科学基金重点项目(2016A030311014)
兰州大学附属第一医院院内基金(ldyyyn2015-17)
关键词
虎杖苷
肝纤维化
TGF-Β1
Α-SMA
Polydatin
Hepatic Fibrosis
Transforming Growth Factor-β1
α-smooth Muscle Actin
